---
input_text: '[Therapy of Wilson disease]. Wilson disease is a copper storage disease
  with autosomal-recessive trait that is predominantly a disorder of the adolescent
  and young adult. Clinical manifestations are dominated by hepatic and/or neurological
  symptoms. Diagnostic procedures include determination of total serum copper, free
  serum copper and serum ceruloplamin concentrations as well as urinary copper excretion.
  Confirmation of diagnosis may be achieved by liver biopsy and histological determination
  of copper content. The aim of treatment is reduction of tissue copper concentration
  and detoxification of copper. Drugs applied are the chelating agents. D-penicillamine
  and trientine, or zinc. The chelating agents induce renal and biliary copper excretion
  and increased synthesis of metallothionein, which attaches and detoxifies intracellular
  copper, leading to impaired absorption and binding of excess intracellular copper.
  Treatment with zinc results in induction of hepatic and intestinal metallothionein
  synthesis. Regular examinations of the parameters of copper metabolism are necessary
  in order to control the therapeutic effect. Free copper serum concentrations and
  urinary copper excretion should reach values below 10 micrograms/dl and 80 micrograms/day,
  respectively. A significant improvement of clinical symptoms and normalization of
  parameters of copper metabolism can be expected earliest six months after onset
  of therapy. Anti-copper treatment may be accompanied by copper-reduced diet. Lifelong
  therapy is required and provides life-expectancy near to normal. Interruption of
  treatment leads to reaccumulation of copper, often resulting in fulminant hepatic
  failure. This can also be observed as initial presentation in 5% of cases (predominant
  age 12 to 25 years). End stage liver disease and fulminant hepatic failure are indications
  for liver transplantation by which the genetic defect is phenotypically cured. Here
  decoppering treatment is no longer required. Whether severe neurological disorders
  may also be improved is not clear until today.'
raw_completion_output: |-
  primary_disease: Wilson disease

  medical_actions: determination of total serum copper; free serum copper and serum ceruloplamin concentrations;determination; urinary copper excretion; liver biopsy; histological determination of copper content; reduction of tissue copper concentration; detoxification of copper; chelating agents; anti-copper treatment; copper-reduced diet; liver transplantation

  symptoms: hepatic symptoms; neurological symptoms; fulminant hepatic failure

  chemicals: D-penicillamine; trientine; zinc

  action_annotation_relationships: determination of total serum copper PREVENTS misdiagnosis IN Wilson disease; free serum copper and serum ceruloplamin concentrations determination PREVENTS misdiagnosis IN Wilson disease; urinary copper excretion determination PREVENTS misdiagnosis IN Wilson disease; liver biopsy TREATS Wilson disease; histological determination of copper content TREATS Wilson disease; reduction of tissue copper concentration TREATS Wilson disease; detoxification of copper TREATS Wilson disease; chelating agents (with D-penicillamine and trientine) TREATS hepatic symptoms IN Wilson disease; chelating agents (with D-penicillamine and trientine) TREATS neurological symptoms IN Wilson disease; zinc TREATS Wilson disease; anti-copper treatment TREATS hepatic symptoms IN Wilson disease; anti-copper treatment TREATS neurological symptoms IN Wilson disease; copper-reduced diet PREVENTS reaccumulation of copper IN Wilson disease; liver transplantation TREATS fulminant hepatic failure IN Wilson disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  liver transplantation TREATS fulminant hepatic failure IN Wilson disease

  ===

extracted_object:
  primary_disease: MONDO:0010200
  medical_actions:
    - determination of total serum copper
    - free serum copper and serum ceruloplamin concentrations
    - determination
    - urinary copper excretion
    - MAXO:0000376
    - histological determination of copper content
    - reduction of tissue copper concentration
    - detoxification of copper
    - chelating agents
    - anti-copper treatment
    - copper-reduced diet
    - MAXO:0001175
  symptoms:
    - hepatic symptoms
    - neurological symptoms
    - HP:0004448
  chemicals:
    - CHEBI:7959
    - CHEBI:39501
    - CHEBI:27363
  action_annotation_relationships:
    - subject: determination of total serum copper
      predicate: PREVENTS
      object: misdiagnosis
      qualifier: MONDO:0010200
    - subject: free serum copper and serum ceruloplamin concentrations determination
      predicate: PREVENTS
      object: misdiagnosis
      qualifier: MONDO:0010200
    - subject: urinary copper excretion determination
      predicate: PREVENTS
      object: misdiagnosis
      qualifier: MONDO:0010200
    - subject: MAXO:0000376
      predicate: TREATS
      object: Wilson disease
    - subject: histological determination of copper content
      predicate: TREATS
      object: Wilson disease
    - subject: reduction of tissue copper concentration
      predicate: TREATS
      object: Wilson disease
    - subject: <detoxification>
      predicate: <TREATS>
      object: <Wilson disease>
      subject_extension: <copper>
    - subject: chelating agents
      predicate: TREATS
      object: hepatic symptoms
      qualifier: MONDO:0010200
      subject_qualifier: with D-penicillamine and trientine
      subject_extension: CHEBI:38161
    - subject: chelating agents TREATS
      predicate: TREATS
      object: neurological symptoms
      qualifier: MONDO:0010200
      subject_qualifier: with D-penicillamine and trientine
      subject_extension: CHEBI:38161
    - predicate: TREATS
      qualifier: MONDO:0010200
      subject_extension: CHEBI:27363
    - subject: treatment
      predicate: TREATS
      object: hepatic symptoms
      qualifier: MONDO:0010200
      subject_extension: anti-copper
    - subject: treatment
      predicate: TREATS
      object: neurological symptoms
      qualifier: MONDO:0010200
      subject_extension: anti-copper
    - subject: copper-reduced diet
      predicate: PREVENTS
      object: reaccumulation of copper
      qualifier: MONDO:0010200
      subject_extension: copper-reduced diet
    - subject: MAXO:0001175
      predicate: TREATS
      object: HP:0004448
      qualifier: MONDO:0010200
named_entities:
  - id: MONDO:0010200
    label: Wilson disease
  - id: MAXO:0001175
    label: liver transplantation
  - id: MAXO:0000004
    label: surgery (laparotomy, rectal mobilization, rectopexy, the partial sigmoid
      colon resection with the primary anastomosis)
  - id: HP:0002910
    label: abnormal liver functions
  - id: HP:0001394
    label: cirrhosis
  - id: CHEBI:27363
    label: zinc
  - id: CHEBI:50868
    label: penicillamine
  - id: CHEBI:51232
    label: Hoechst 33342
  - id: HP:0006554
    label: acute liver failure
  - id: MAXO:0000068
    label: transplantation
  - id: MAXO:0009095
    label: Zinc therapy
  - id: HP:0002344
    label: Neurologic deterioration
  - id: MAXO:0001298
    label: therapy
  - id: HP:0001392
    label: liver disease
  - id: HP:0006579
    label: neonatal jaundice
  - id: HP:0002612
    label: congenital hepatic fibrosis
  - id: HP:0001409
    label: portal hypertension
  - id: HP:0030151
    label: cholangitis
  - id: MONDO:0013282
    label: alpha-1-antitrypsin deficiency
  - id: MONDO:0009061
    label: cystic fibrosis
  - id: MONDO:0009044
    label: Crigler-Najjar syndrome
  - id: MAXO:0000376
    label: liver biopsy
  - id: MAXO:0000127
    label: genetic testing
  - id: HP:0001903
    label: anemia
  - id: HP:0001410
    label: liver dysfunction
  - id: CHEBI:39501
    label: trientine
  - id: CHEBI:28694
    label: copper
  - id: HP:0001399
    label: hepatic failure
  - id: HP:0004448
    label: fulminant hepatic failure
  - id: CHEBI:35341
    label: Steroids
  - id: CHEBI:33281
    label: Antibiotics
  - id: MONDO:0100193
    label: end-stage liver disease
  - id: HP:0100626
    label: end-stage liver disease
  - id: HP:0100660
    label: dyskinesia
  - id: HP:0004787
    label: fulminant hepatitis
  - id: HP:0031811
    label: bilirubinuria
  - id: HP:0001397
    label: hepatic steatosis
  - id: CHEBI:16359
    label: cholic acid
  - id: MONDO:0019542
    label: Acute liver failure (ALF)
  - id: HP:0002480
    label: Hepatic encephalopathy
  - id: CHEBI:27385
    label: CCL4
  - id: MAXO:0001017
    label: Vaccination
  - id: HP:0001541
    label: Ascites
  - id: HP:0012398
    label: Peripheral edema
  - id: HP:0001337
    label: tremor
  - id: HP:0001260
    label: dysarthria
  - id: HP:0000708
    label: psychiatric disorders
  - id: HP:0200123
    label: chronic hepatitis
  - id: CHEBI:38161
    label: chelators
  - id: MAXO:0000603
    label: peritoneal dialysis
  - id: CHEBI:7959
    label: D-penicillamine
  - id: HP:0200032
    label: Kayser-Fleischer rings
  - id: HP:0002172
    label: imbalance
  - id: HP:0000093
    label: proteinuria
  - id: HP:0032199
    label: abnormal prothrombin time
  - id: MAXO:0000167
    label: Antiepileptic therapy
  - id: CHEBI:61049
    label: Tacrolimus
  - id: CHEBI:9168
    label: Rapamycin
  - id: CHEBI:55379
    label: Cyclosporine (CsA)
  - id: CHEBI:35623
    label: antiepileptic
  - id: CHEBI:4031
    label: Cyclosporine
  - id: HP:0000083
    label: renal failure
  - id: CHEBI:26708
    label: NA
  - id: CHEBI:35176
    label: zinc sulphate
  - id: HP:0001251
    label: ataxia
  - id: CHEBI:166831
    label: copper chelators
  - id: HP:0006577
    label: macronodular cirrhosis
  - id: CHEBI:8830
    label: rhodanine
  - id: CHEBI:18248
    label: iron
  - id: HP:0002015
    label: dysphagia
  - id: MONDO:0021200
    label: Rare diseases
  - id: MAXO:0000011
    label: Physiotherapy
  - id: MONDO:0001516
    label: spinal muscular atrophy
  - id: HP:0100806
    label: Sepsis
  - id: CHEBI:2948
    label: Azathioprine
  - id: CHEBI:8378
    label: Prednisolone
  - id: HP:0031690
    label: opportunistic infections
  - id: HP:0001513
    label: Obesity
  - id: HP:0000819
    label: Diabetes
  - id: HP:0002829
    label: Arthralgia
  - id: HP:0003281
    label: Elevated serum ferritin
  - id: HP:0012463
    label: Elevated transferrin saturation
  - id: CHEBI:9907
    label: Ursodeoxycholic acid
  - id: MONDO:0007027
    label: Non-alcoholic steatohepatitis (NASH)
  - id: MONDO:0006507
    label: Hereditary hemochromatosis (HH)
  - id: HP:0003256
    label: Coagulopathy
  - id: HP:0001298
    label: Encephalopathy
  - id: HP:0000952
    label: Jaundice
  - id: HP:0001289
    label: Confusion
  - id: MONDO:0003441
    label: dystonia
  - id: MAXO:0009015
    label: botulinum toxin injection
  - id: MAXO:0000943
    label: deep brain stimulation
  - id: CHEBI:9720
    label: trihexyphenidyl
  - id: HP:0001332
    label: dystonia
  - id: HP:0004305
    label: involuntary movements
  - id: CHEBI:46195
    label: acetaminophen
  - id: HP:0100520
    label: oliguria
  - id: CHEBI:16737
    label: creatinine
  - id: HP:0003259
    label: elevated creatinine
  - id: HP:0100543
    label: Cognitive impairment
  - id: CHEBI:33234
    label: vitamin E
  - id: MAXO:0000070
    label: Hepatic transplantation
  - id: HP:0001942
    label: metabolic acidosis
  - id: HP:0001953
    label: diabetic ketoacidosis (DKA)
  - id: CHEBI:145810
    label: insulin
  - id: HP:0003781
    label: Hypersalivation
  - id: HP:0002315
    label: Headache
  - id: HP:0002027
    label: Abdominal pain
  - id: HP:0002240
    label: Hepatomegaly
  - id: HP:0001744
    label: Splenomegaly
  - id: HP:0001873
    label: Thrombocytopenia
  - id: HP:0001250
    label: Convulsions
  - id: HP:0100785
    label: Insomnia
  - id: HP:0003394
    label: Muscle cramps
  - id: HP:0003401
    label: Paresthesia
  - id: HP:0025406
    label: Weakness
  - id: CHEBI:8764
    label: Mycophenolate mofetil
  - id: MONDO:0019737
    label: Thrombotic microangiopathy (TMA)
  - id: CHEBI:37153
    label: calcineurin inhibitors
  - id: MAXO:0001001
    label: gene therapy
  - id: CHEBI:30703
    label: tetrathiomolybdate
  - id: HP:0002878
    label: respiratory failure
  - id: HP:0001892
    label: hemorrhagic diathesis
